Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month
Bausch Health Companies (BHC) shares rose nearly 40% in July after a Canada regulatory update and a beat-and-raise quarter. Prokedi was added to Quebec’s formulary. In Q2, revenue and adjusted results improved, with adjusted EPS $1.26 vs $1.23 expected, and net income $476M. Bausch raised 2026 revenue to $10.79B-$11.04B and adjusted EBITDA to $4.05B-$4.18B.
How this was made
The 30-second read
Why it matters
For traders, the key actionable items are the Quebec formulary addition timing and the raised 2026 revenue and adjusted EBITDA guidance ranges, which can affect valuation and expectations for the next earnings cycle.
Market read
A regulatory formulary addition and a guidance raise provide a clear fundamental catalyst set, supporting bullish positioning but with potential for post-run consolidation.
What to watch
The article notes one unit with flat revenue and that Bausch + Lomb is a relative laggard; investors may scrutinize whether growth is concentrated in a few segments or products.
Background
The article attributes Bausch Health’s nearly 40% July gain to a Canada regulatory win for Prokedi and a subsequent Q2 beat-and-raise.
Ticker impact
Bausch Health added Prokedi to Quebec’s formulary on July 6, then reported Q2 beat-and-raise with higher 2026 revenue and adjusted EBITDA guidance.
Near-term follow-through possible if investors focus on sustained guidance, but upside may be capped given the large prior month rally.
The article cites two concrete catalysts: Quebec formulary inclusion for Prokedi and specific Q2 financial beats plus raised 2026 revenue and adjusted EBITDA ranges.
Market effects
Reinforces the market’s willingness to reward pharma names with incremental formulary wins and credible guidance raises.
Highlights Canada, specifically Quebec formulary inclusion, as a near-term demand/access driver for branded schizophrenia therapy.
Supports broader investor confidence in specialty pharma execution and portfolio momentum, though impact is primarily company-specific.
Counterpoint
The stock’s large July run may mean the incremental value of the Quebec formulary addition is already priced, leaving limited incremental upside unless subsequent quarters confirm sustained growth.
Key entities
- companyBausch Health Companies
Subject of the article, with Prokedi formulary addition in Quebec and Q2 beat plus raised 2026 guidance.
- drugProkedi
Bausch schizophrenia drug added to Quebec’s formulary, improving commercialization pathway in Canada.
- regulatorQuebec Health Insurance Board
Province-level formulary body that added Prokedi, following federal Health Canada approval.
- executiveThomas Appio
CEO quoted attributing performance to portfolio strength and execution.
